25th week of 2014 patent applcation highlights part 63 |
Patent application number | Title | Published |
20140171458 | INTRANASAL NALTREXONE - A stable transmucosal composition consisting essentially of naltrexone hydrochloride in water is provided. The composition is surprisingly stable at room temperature and can be used for simple, rapid and effective opioid overdose rescue. | 2014-06-19 |
20140171459 | METHODS FOR TREATING PRURITUS - The present invention relates to methods for treating pruritus with anti-pruritic compositions. | 2014-06-19 |
20140171460 | METHODS AND COMPOSITIONS FOR TREATMENT OF EPITHELIAL WOUNDS - This invention relates to treatment of epithelial wounds. In particular, the invention relates to methods and formulations for treating epithelial wounds based on application of an opioid antagonist such as naltrexone. | 2014-06-19 |
20140171461 | Nitrogen Containing Morphinan Derivatives and the Use Thereof - The application is directed to compounds of Formula I-A | 2014-06-19 |
20140171462 | 4-(8-METHOXY-1-((1-METHOXYPROPAN-2-YL)-2-(TETRAHYDRO-2H-PYRAN-4-YL)-1 H-IMIDAZO[4,5-C]QUINOLIN-7-YL)-3,5-DIMETHYLISOXAZOLE AND ITS USE AS BROMODOMAIN INHIBITOR - Novel quinoline compounds pharmaceutical compositions containing such compounds and their use in therapy. | 2014-06-19 |
20140171463 | TREATMENT OF PROGRESSIVE NEURODEGENERATIVE DISEASE WITH IBUDILAST - Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine). | 2014-06-19 |
20140171464 | PHARMACEUTICAL COMPOSITION CONTAINING DIAMINE DERIVATIVE - An object of the present invention is to provide a pharmaceutical composition containing compound I or a pharmacologically acceptable salt thereof, or a solvate thereof as an active ingredient, which is favorably dissolved in the neutral region. The present invention relates to a pharmaceutical composition containing (A) N | 2014-06-19 |
20140171465 | Methods For Increasing Reticulocyte Hemoglobin Content - The invention relates to methods and compounds useful for treating deficiencies in hemoglobin production. Methods and compounds useful for increasing reticulocyte hemoglobin content are provided. | 2014-06-19 |
20140171466 | PAIN MANAGEMENT IN SICKLE CELL ANEMIA - The present invention relates to a method for the management of pain associated with sickle cell disease. In particular, the method comprises administering to a patient in need of such pain management a therapeutically effective amount of a nociceptin (NOP) receptor agonist or an NOP receptor agonist/mu opioid receptor (MOR) partial agonist. | 2014-06-19 |
20140171467 | INHIBITORS OF NCCA-ATP CHANNELS FOR THERAPY - Methods and compositions are provided that are utilized for treatment and/or prevention of intraventricular hemorrhage or progressive hemorrhagic necrosis (PHN), particularly following spinal cord injury. In particular, the methods and compositions are inhibitors of a particular NCca-ATP channel and include, for example, inhibitors of SURI and/or inhibitors of TRPM4. Kits for treatment and/or prevention of intraventricular hemorrhage or progressive hemorrhagic necrosis (PHN), particularly following spinal cord injury, are also provided. The present invention also concerns treatment and/or prevention of intraventricular hemorrhage in infants, including premature infants utilizing one or more inhibitors of the channel is provided to the infant, for example to brain cells of the infant. | 2014-06-19 |
20140171468 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF - The present invention relates to methods of treating androgen deprivation therapy (ADT) induced hot flashes and severe hot flashes in a subject. | 2014-06-19 |
20140171469 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO - Pyrazole derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD). | 2014-06-19 |
20140171470 | POLYMORPHS OF (S)-PYRROLIDINE-1,2-DICARBOXYLIC ACID 2-AMIDE 1-(-AMIDE - The present invention relates to specific solid forms of (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-(4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl)-amide, and its solvates. The present invention further relates to processes for preparing said solid forms, pharmaceutical compositions comprising said solid forms, and methods of using said solid forms and pharmaceutical compositions to treat disease. | 2014-06-19 |
20140171471 | HAIR CARE PRODUCTS WITH ANTI-DANDRUFF AGENTS AND CATIONIC PLANT-BASED SURFACTANTS - Compositions for treating keratinic fibers, in particular human hair, that exhibit, in addition to conditioning properties as well as the shine and haptics of keratinic fibers, in particular human hair, impart an improved effect with regard to the removal of dandruff on the keratinic fibers. | 2014-06-19 |
20140171472 | Pyridoxamine for the Treatment of Diabetic Kidney Disease - The present invention provides pharmaceutical compositions comprising dosage units of pyridoxamine, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, and methods for their use in limiting the progression of renal disease and/or diabetic complications in human diabetic patient. | 2014-06-19 |
20140171473 | POLYMORPHIC FORMS OF THE SODIUM SALT OF 4-TERT- BUTYL -N-[4-CHLORO-2-(1-OXY-PYRIDINE-4-CARBONYL)-PHENYL]-BENZENE SULFONAMIDE - Disclosed are novel novel polymorphic solvated and desolvated forms of the sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)phenyl]-benzenesulfonamide. One embodiment of the present invention is directed to a crystalline sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]benzenesulfonamide (hereinafter “Compound A-1,4-dioxane/water solvate”), wherein the crystalline form is characterized by an X-ray powder diffraction pattern comprising diffraction angles (° 28), when measured using Cu Ku radiation, at about 4.0,8.1, 10.1, 14.2, 16.2, 18.6,20.3,24.7,25.0, and 26.5. | 2014-06-19 |
20140171474 | FUNGICIDE N-CYCLOALKYL-N-BIPHENYLMETHYL-CARBOXAMIDE DERIVATIVES - The present invention relates to N-cycloalkyl-N-biphenylmethyl-carboxamide derivatives of formula (I) | 2014-06-19 |
20140171475 | ANIMAL ECTOPARASITE-CONTROLLING AGENT - An animal ectoparasite-controlling agent comprising a benzylamide compound represented by the formula (1): wherein R | 2014-06-19 |
20140171476 | Chemical Compounds - Disclosed are compounds of Formula I, Formula II, and Formula III. Also disclosed are salts of the compounds, pharmaceutical composition comprising the compounds or salts, and methods for treating HCV infection by administration of the compounds or salts. | 2014-06-19 |
20140171477 | DERIVATIVES OF CELEBOXIB, USE THEREOF AND PREPARATION THEREOF - Derivatives of celecoxib that lack cyclooxygenase inhibitory activity but have improved PDE5 inhibitory activity are provided along with pharmaceutical compositions containing them for the treatment or prevention of cancer. Such compounds are expected to have reduced toxicity compared with celecoxib and other cyclooxygenase inhibitors, and greater efficacy compared with conventional PDE5 inhibitors. Derivatives of celecoxib are also suitable for treating chronic inflammatory conditions, erectile dysfunction, pulmonary hypertension, congestive heart failure, and enhancement of cognitive function. | 2014-06-19 |
20140171478 | CONTROLLED-RELEASE MELATONIN COMPOSITIONS AND RELATED METHODS - A melatonin-containing product includes a composition comprising melatonin, a pH lowering agent, and a gel-forming forming polymer. When ingested, the composition forms an acidic aqueous gel matrix having melatonin dissolved therein for releasing melatonin into the intestines for a sustained time period. | 2014-06-19 |
20140171479 | MELATONIN TREATMENT METHODS - A method of treating a human subject in need of melatonin therapy comprises administering to a human subject a composition comprising melatonin dispersed in a polymer matrix adapted to cover the melatonin in a melatonin solubility enhancing pH environment after ingestion and to maintain the melatonin solubility enhancing pH environment when said composition is present in said subject's intestines so that an effective amount of melatonin is released into the subject's intestines. | 2014-06-19 |
20140171480 | CRYSTALLINE POLYMORPHIC FORMS OF AN ANTIDIABETIC COMPOUND - The present invention relates to polymorphic forms of a compound of formula A: | 2014-06-19 |
20140171481 | SOLID COMPOSITIONS - The present invention features solid compositions comprising amorphous Compound I. For instance, Compound I may be formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant. | 2014-06-19 |
20140171482 | Nanotubes as Carriers of Nucleic Acids into Cells - The present invention is directed to transfection complexes of rosette nanotubes and one or more nucleic acids. | 2014-06-19 |
20140171483 | COMPOSITIONS AND METHODS FOR TREATMENT OF TAMOXIFEN RESISTANT BREAST CANCER - The inventors found that the gene, HOXB7, was frequently overexpressed in breast cancer, and is a major upstream regulator of events leading to tamoxifen resistance. The present invention provides double-stranded short interfering nucleic acid (siNA) molecules that targets the HOXB7 gene in cells, and also provides methods of use of this siNA molecule for methods of screening, diagnosis and prediction of treatment outcomes as well as treatment of cancer. | 2014-06-19 |
20140171484 | TISSUE-SPECIFIC MICRORNAS AND COMPOSITIONS AND USES THEREOF - The invention provides for isolated nucleic acid sequences of newly discovered micro RNAs that have been identified to exist in normal Human B cells and/or in tumor-related Human B cells, using an integrated bioinformatics method and pipeline described herein. | 2014-06-19 |
20140171485 | MODIFIED POLYNUCLEOTIDES ENCODING CD28 MOLECULE - The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules. | 2014-06-19 |
20140171486 | Single-Stranded Nucleic Acid Molecule Having Nitrogen-Containing Alicyclic Skeleton - Provided is a novel nucleic acid molecule that can be produced easily and efficiently and can inhibit the expression of a gene. The nucleic acid molecule is a single-stranded nucleic acid molecule including an expression inhibitory sequence that inhibits expression of a target gene. The single-stranded nucleic acid molecule includes: a region (X); a linker region (Lx); and a region (Xc). The linker region (Lx) is linked between the regions (Xc) and (Xc). The region (Xc) is complementary to the region (X). At least one of the regions (X) and (Xc) includes the expression inhibitory sequence. The linker region (Lx) has a non-nucleotide structure including at least one of a pyrrolidine skeleton and a piperidine skeleton. According to this single-stranded nucleic acid molecule, it is possible to inhibit the expression of the target gene. | 2014-06-19 |
20140171487 | RNAi-MEDIATED INHIBITION OF PHOSPHODIESTERASE TYPE 4 FOR TREATMENT OF cAMP-RELATED OCULAR DISORDERS - RNA interference is provided for inhibition of phosphodiesterase type 4 mRNA expression for treating patients with a cAMP-related ocular disorder. Phosphodiesterase type 4 mRNA targets include mRNA for 4A, 4B, 4C, and 4D phosphodiesterase isoforms. | 2014-06-19 |
20140171488 | COMPOSITION FOR INHIBITING ANGIOGENESIS CONTAINING A PEROXIDASIN INHIBITOR AS AN ACTIVE INGREDIENT - The invention relates to a composition for angiogenesis inhibition comprising a peroxidasin inhibitor as an effective ingredient, and more particularly, to a method of screening angiogenesis inhibitor, which includes steps of treating a test agent, and analyzing peroxidasin gene expression or protein activity, and comparing peroxidasin gene expression or protein activity between a case treated with the test agent and a case not treated with the test agent. Accordingly, since the inhibitor of the peroxidasin expression or protein activity according to the present invention can effectively inhibit migration, proliferation and tube formation of endothelial cells, the inhibitor can be effectively used for preventing or treating a variety of diseases or conditions of the diseases derived from abnormal regulation of angiogenesis. | 2014-06-19 |
20140171489 | HUMAN RESISTIN RECEPTOR AND USE THEREOF - The present invention concerns a human resistin receptor. More particularly, the present invention provides a method for screening a receptor of human resistin protein, a method for preventing or treating an inflammatory disease and arteriosclerosis using an expression- or activity-regulator for a human resistin receptor, and a pharmaceutical composition including an expression- or activity-regulator for the human resistin receptor. The method for screening a human resistin protein receptor according to the present invention enables separation of a receptor which directly binds to resistin from human monocyte, reveals a mechanism of signal transduction of the resistin receptor, and therefore, is expected to contribute to regulation of an inflammatory effect of monocyte, molecular detection of causes for vascular inflammation and arteriosclerosis, and developments of prevention and a treating agent for an inflammatory disease and arteriosclerosis. | 2014-06-19 |
20140171490 | Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients - Disclosed is the use of a mist of a pharmaceutical composition for ophthalmic delivery of a protein or peptide active pharmaceutical ingredient, a related method of treatment and a device useful in implementing the use and method. Disclosed is also the use of a mist for ophthalmic delivery of a pharmaceutical composition including a highly irritating penetration enhancer and an ophthalmically acceptable carrier, a related method of treatment and a device useful in implementing the use and method. Disclosed is also a device for ophthalmic administration configured to direct a mist of a pharmaceutical composition to the eye only when the eye is open. Disclosed is also a self-sterlizing device for ophthalmic administration. Disclosed is also a device and a method for increasing the bioavailability of an ophthalmically administered API in a pharmaceutical composition. | 2014-06-19 |
20140171491 | INTRANASAL DELIVERY OF AAV ENCODING THERAPEUTIC ENZYMES TO THE CENTRAL NERVOUS SYSTEM FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES - The invention provides a method to prevent, inhibit or treat one or more neurological symptoms associated with a lysosomal storage disease in a mammal in need thereof, which includes intranasally administering to the mammal a composition comprising an effective amount of a lysosomal storage enzyme or a recombinant adeno-associated virus vector comprising an open reading frame encoding a lysosomal storage enzyme. Also provided are compositions and devices useful in the methods. | 2014-06-19 |
20140171492 | CHIMERIC RNA OLIGONUCLEOTIDES AND USES THEREOF - The present invention relates to chimeric RNA oligonucleotides that are single-stranded oligonucleotides. These compounds are capable of targeting particular genes and reducing DNA methyltransferase activity. Accordingly, these compounds are particularly useful in the treatment of disease associated with aberrant DNA methyltransferase activity, such as cancer or a genetic disorder. | 2014-06-19 |
20140171493 | HIGHLY FUNCTIONAL ENZYME HAVING ALPHA-GALACTOSIDASE ACTIVITY - The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having α-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired α-galactosidase activity by changing the structure of the active site of wild-type human α-N-acetylgalactosaminidase. | 2014-06-19 |
20140171494 | USE OF INTEGRASE FOR TARGETED GENE EXPRESSION - There are provided methods and compositions for activating the expression of an exogenous gene by an exogenous integrase specifically in cells in which the exogenous integrase is expressed. The invention further relates to uses of the compositions in treatment of various conditions and disorders, as exemplified by selectively activating expression of a toxin only in target cell populations. | 2014-06-19 |
20140171495 | STABLE PHARMACEUTICAL FORMULATION OF CABAZITAXEL - The present invention relates to a stable liquid cabazitaxel formulation in an enclosed container. The enclosed container comprises a liquid phase and an gaseous phase, wherein the liquid phase comprises cabazitaxel, polysorbate 80, ethanol, and one or more pH adjusters to maintain pH about 2.8-6.0, and the gaseous phase is saturated with CO | 2014-06-19 |
20140171496 | COMPOSITION AND METHOD FOR PROMOTING HAIR GROWTH - The present invention provides a method and composition for promoting hair growth in a mammal which comprises a prostaglandin compound having two hetero atoms at the 15 position as an active ingredient thereof. | 2014-06-19 |
20140171497 | ANIMAL SUPPLEMENTS AND COMPOSITIONS CONTAINING SOLUABLE MONENSIN AND METHODS THEREFOR - The present disclosure provides animal feed supplements comprising a therapeutically effective amount of monensin and a solvent, wherein the supplement is a solution. The disclosure also provides food compositions comprising a therapeutically effective amount of monensin, a solvent, and an animal feed, methods of administering the food compositions, and processes for making the food compositions. | 2014-06-19 |
20140171498 | C-9 OXYGEN FUNCTIONALIZED LABDANE DERIVATES - This invention relates to diterpenes of general formula (1) belonging to labdane class, isolated from | 2014-06-19 |
20140171499 | Pseudopolymorphic Forms Of A HIV Protease Inhibitor - New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate and processes for producing them are disclosed. | 2014-06-19 |
20140171500 | Health promoting drink - The present invention relates a new drink formula comprising fresh marine omega-3 oil in an emulsion and antioxidants well known to be health promoting to humans, and process for the production of said drink and the use of said drink for production of a medicament. | 2014-06-19 |
20140171501 | COMPLEX ZINC AND ALPHA-CHLOROCARBOXYLIC ACID COMPOUNDS FOR TREATING SKIN LESIONS - The invention relates to the field of medicine, and specifically to preparations for treating skin lesions, in particular viral, benign, precancerous and cancerous, non-metastasizing, dysplastic and inflammatory lesions of the visible mucous membranes, and also viral and fungal skin and nail lesions, and for correcting wrinkles and senile pigment blemishes, said preparations comprising solutions of complex compounds of salts of zinc and alpha-chlorocarboxylic acids of general formula [Zn(RCH | 2014-06-19 |
20140171502 | New Process - The present invention relates to a process for the preparation of S-[2-[1-(2-ethylbutyl)cyclohexylcarbonylamino]-phenyl] 2-methylthiopropionate which is useful as a pharmaceutically active compound. | 2014-06-19 |
20140171503 | NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER - Disclosed are compounds which are nuclear receptor modulators that can act as antagonists to the androgen receptor, for example, a compound of Formula I: wherein R | 2014-06-19 |
20140171504 | Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters - Methods of using one or more fumaric acid esters or pharmacologically active salts, derivatives, analogues, or prodrugs thereof to increase expression of fetal hemoglobin (HbF) are disclosed. The methods typically include administering to a subject an effective amount of one or more fumaric acid esters optionally in combination or alternation with hydroxyurea to induce HbF expression in the subject in an effective amount to reduce one or more symptoms of a sickle cell disorder, a hemoglobinopathy, or a beta-thalassemia, or to compensate for a genetic mutation is the human beta-globin gene (HBB) or an expression control sequence thereof. Pharmaceutical dosage units and dosage regimes for use in the disclosed methods are also provided. | 2014-06-19 |
20140171505 | GAMMA-HYDROXYBUTYRATE COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF DISORDERS - Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus. | 2014-06-19 |
20140171506 | GAMMA-HYDROXYBUTYRATE COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF DISORDERS - Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus. | 2014-06-19 |
20140171507 | AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN - The invention relates to compounds, to compositions comprising the same and uses thereof for the prevention or treatment of pain, e.g neuropathic pain while having neutral or beneficial effect on metabolic parameters. | 2014-06-19 |
20140171508 | METHOD OF TREATING PARKINSON'S DISEASE COMPRISING ADMINISTERING DEFEROXAMINE (DFO) TO THE UPPER ONE-THIRD OF THE NASAL CAVITY - Methods and pharmaceutical compositions for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and stabilizing hypoxia-inducible factor-1α (HIF-1α). HIF-1α is known to provide a neuroprotective benefit under ischemic conditions. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease or stroke or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). Intranasal administration of DFO is known to stimulate and/or stabilize HIF-1α and provides an efficient and safe method for pre-conditioning the brain to protect against cerebral ischemia. Moreover, DFO is shown to decrease weight loss in subjects when administered pre and/or post stroke. | 2014-06-19 |
20140171509 | Non-Aqueous Patch - Non-aqueous patches comprising lidocaine, which is not dissolved and is present in a crystalline state, have poor permeability to the skin. Therefore, non-aqueous patches have a high concentration of lidocaine. It is pointed out that lidocaine has an adverse effect on the heart. Prolonged use of a high concentration of lidocaine causes side effects, such as shock, rubor, and irritating sensation. External preparations comprising more than 5 mass % of lidocaine are designated as powerful drugs, and cannot be used as household (nonprescription) medicine. Provided is a non-aqueous patch that is effective to relieve muscle pain, the non-aqueous patch comprising lidocaine and/or its reactant, and a dissolving agent composed of an organic acid and a polyalcohol, which are contained in a base. | 2014-06-19 |
20140171511 | Cough Reducing Product - The present invention relates to a product comprising capsaicin or a capsaicinoid for use in the treatment of cough, in particular chronic persistent unexplained cough or increased cough reflex sensitivity. More precisely, the invention concerns oral formulations for reducing and relieving coughing from other irritants than capsaicin itself. The capsaicin formulations are stated to down-regulate coughing following a regular consumption. Said products can also be used in the treatment of rhinitis and other conditions known to have cough symptoms. | 2014-06-19 |
20140171512 | FOOD CONTACT DISINFECTING/SANITIZING FORMULATION AND WIPE - Disclosed is a sanitizing/disinfecting composition containing a quaternary ammonium compound and a polybiguanide. The composition is a food contact safe composition which does not need rinsing after being applied to a substrate. The composition may be saturated into a wipe. | 2014-06-19 |
20140171513 | FOAMING SANITIZING FORMULATIONS AND PRODUCTS INCLUDING A QUATERNARY AMMONIUM COMPOUND - Foaming formulations including a quaternary ammonium compound and a foam stabilizer are disclosed. These foaming formulations are useful as leave-on liquid hand and surface sanitizers. The foaming formulations provide improved aesthetic properties and foaming appearance, while maintaining high antimicrobial capacity. | 2014-06-19 |
20140171514 | NMDA RECEPTOR ANTAGONIST FORMULATION WITH REDUCED NEUROTOXICITY - The present invention is directed to pharmaceutical compositions of effective amounts of NMDA receptor antagonists and preservative for the administration to a patient in need of effective analgesia and anesthesia. The compositions of the invention advantageously do not cause any significant neurotoxicity. The preferred NMDA receptor antagonist is ketamine. The preferred preservative is benzalkonium chloride. | 2014-06-19 |
20140171515 | COMPOSITIONS AND METHODS FOR TRANSMUCOSAL ABSORPTION - The invention provides compositions and methods for administering compounds for transmucosal absorption. The compositions and methods have a number of surprising pharmacokinetic benefits over oral administration of a compound. | 2014-06-19 |
20140171516 | GERANYLGERANYLACETONE FORMULATIONS - Provided herein is a pharmaceutical formulation comprising at least one geranylgeranyl acetone in the form of an eye drop. Also provided herein are methods of treating neural diseases or disorders by administering such pharmaceutical formulations. | 2014-06-19 |
20140171517 | 2-MERCAPTO-5-METHYL-4-HEPTANONE AND ITS USE IN FLAVOR AND FRAGRANCE COMPOSITIONS - The present invention is directed to a novel compound, 2-mercapto-5-methyl-4-heptanone, a process of augmenting, enhancing or imparting taste to a material selected from the group consisting of a foodstuff, a chewing gum, a medicinal product, and toothpaste comprising the step of incorporating an olfactory acceptable amount of 2-mercapto-5-methyl-4-heptanone, and a process of improving, enhancing or modifying a fragrance formulation through the addition of an olfactory acceptable amount of 2-mercapto-5-methyl-4-heptanone. | 2014-06-19 |
20140171518 | STABLE AND COMPATIBLE POLYMER BLENDS - The present invention pertains to products and processes relating to compatible polymer blends comprising at least one sulfonated polymer and at least one non-sulfonated polymer. The sulfonated polymers may be produced using a number of sulfonating agents including a coordination complex of sulfur trioxide. The polymeric blended materials described herein are useful in a variety of applications, including as coatings for medical devices, protective clothing and fabric, laboratory equipment, vascular stents and shunts, absorbent materials and separation membranes, three-dimensional constructs, devices, and other uses. | 2014-06-19 |
20140171519 | COMPOSITIONS AND METHODS FOR IMPROVING REBAUDIOSIDE X SOLUBILITY - Polymorphic and amorphous forms of Rebaudioside X and methods for preparing the same are provided herein. Also provided herein are Rebaudioside X complexes and methods for preparing the same. Sweetener compositions and sweetened compositions comprising Rebaudioside X forms and Rebaudioside X complexes are described, as well as and methods of their preparation. Methods of improving the flavor and/or temporal profile of sweetenable compositions, such as beverages, are also provided herein. | 2014-06-19 |
20140171520 | HIGHLY SOLUBLE STEVIA SWEETENER - A method for making highly soluble | 2014-06-19 |
20140171521 | HIGHLY FUNCTIONAL CELLULOSE COMPOSITE - A cellulose composite which contains a cellulose and a polysaccharide and which is characterized in that the median diameter of colloidal cellulose composites contained in the cellulose composite is 0.85 μm or more as measured by a dynamic light scattering method. | 2014-06-19 |
20140171522 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Heat shock protein beta-1, WAP four-disulfide core domain protein 2, Choriogonadotropin subunit beta, Placenta growth factor, and Mitochondrial 60 kDa heat shock protein as diagnostic and prognostic biomarkers in renal injuries. | 2014-06-19 |
20140171523 | METHOD FOR MANUFACTURE OF PURE, CARBON FREE NANOPARTICLES - The invention provides a process for the production of nanoparticles as well as a device that is disposed for the production of the nanoparticles. The process is especially characterized in that the nanoparticles are pure, especially free from organic carbon compounds, preferably carbon-free, and are obtained continuously. The nanoparticles which are obtainable by the process of the invention are characterized in that they are present without an organic ligand in suspension and are especially preferred stable as a suspension against agglomeration, wherein the medium having the particles suspended therein is free from organic carbon compounds, especially carbon-free. | 2014-06-19 |
20140171524 | POLYVINYLIDENE FLUORIDE RESIN EXPANDED BEADS, METHOD FOR PRODUCING POLYVINYLIDENE FLUORIDE RESIN EXPANDED BEADS, AND MOLDED ARTICLES OF POLYVINYLIDENE FLUORIDE RESIN EXPANDED BEADS - There is provided polyvinylidene fluoride resin expanded beads which have a high expansion ratio, do not shrink easily, and are capable of obtaining a molded article of the expanded beads that is excellent in mold reproducibility and dimensional stability. The polyvinylidene fluoride resin expanded beads include a polyvinylidene fluoride resin as a base resin, in which a flexural modulus of the polyvinylidene fluoride resin is 450 MPa or more, a melt flow rate (MFR) of the polyvinylidene fluoride resin is 1 g/10 min or more at 230° C. and 2.16 kg load, an apparent density of the expanded beads is 25 to 150 g/L, and a closed cell content of the expanded beads is 80% or more. | 2014-06-19 |
20140171525 | POLYURETHANE FOAM PREMIXES CONTAINING HALOGENATED OLEFIN BLOWING AGENTS AND FOAMS MADE FROM SAME - Disclosed are polyol premix compositions, and foams formed therefrom, which comprise a combination of a hydrohaloolefin blowing agent, a polyol, a silicone surfactant, and a catalyst system that includes a bismuth-based metal catalyst. Such catalysts may be used alone or in combination with an amine catalyst and/or other non-amine catalysts. | 2014-06-19 |
20140171526 | POROUS BRANCHED/HIGHLY BRANCHED POLYIMIDES - The present invention relates to a process for the preparation of porous particles comprising at least one polyimide by reacting (A) at least one polyisocyanate having on average at least two isocyanate groups per molecule and (B) at least one polycarboxylic acid having at least two COOH groups per molecule or anhydride thereof, in the presence of at least one solvent, optionally at least one catalyst and optionally at least one further additive, to cause precipitation of a polyimide in the solvent to form the porous particles, to porous particles, obtained with this process, to parts, bodies, foams and/or material comprising these porous particles, and to the use of the porous particles or of the parts, bodies, foams and/or material as insulation material and in vacuum insulation. | 2014-06-19 |
20140171527 | POLYURETHANE FOAM PREMIXES CONTAINING HALOGENATED OLEFIN BLOWING AGENTS AND FOAMS MADE FROM SAME - The invention provides polyurethane and polyisocyanurate foams and methods for the preparation thereof. More particularly, the invention relates to closed-celled, polyurethane and polyisocyanurate foams and methods for their preparation. The foams are characterized by a fine uniform cell structure and little or no foam collapse. The foams are produced with a polyol premix composition which comprises a combination of a hydrohaloolefin blowing agent, a polyol, a silicone surfactant, and a precipitation-resistant metal-based catalyst used alone or in combination with an amine catalyst. | 2014-06-19 |
20140171528 | MULTI-FUNCTIONAL BIO POLYURETHANE FOAM - Disclosed is a multi-functional bio polyurethane foam, and more specifically a multi-functional bio polyurethane foam which is polyurethane foam comprising a reaction product of a resin premix, which comprises about 5 to 20 wt % biopolyol, and isocyanate. The multi-functional bio polyurethane foam may be applied to a car seat and the like, and shows the same level of physical properties as the conventional polyurethane foam manufactured from the petroleum-based polyol, and further provides enhanced antimicrobial function and minimized vibration transmissivity. | 2014-06-19 |
20140171529 | ANTIMICROBIAL BIO POLYURETHANE FOAM - Disclosed is an antimicrobial bio polyurethane foam, and more specifically abio polyurethane foam: which is polyurethane foam comprising a reaction product of a resin premix, which comprises biopolyol of about 5 to 20 wt %, and isocyanate; applied to a car seat and the like; and which is enhanced in an antimicrobial property through use of the biopolyol. | 2014-06-19 |
20140171530 | Method of Making Foam - A method of making a foam from a polymerizable resin includes the following steps. A thermally-activated initiator having a temperature below the initiation temperature is combined with an elevated-temperature solution having the polymerizable resin and carbon dioxide at a temperature above a promoted temperature to create a resulting mixture having a temperature above the promoted temperature. The resulting mixture is expanded by decreasing the pressure of the mixture to create a froth having a plurality of cells formed by carbon dioxide that expanded out of solution. The polymerizable resin within the froth is cured to create a foam. | 2014-06-19 |
20140171531 | ANTIMICROBIAL BIO POLYURETHANE FOAM AND METHOD FOR MANUFACTURING THE SAME - Disclosed is an antimicrobial bio polyurethane foam and a method for manufacturing thereof, and more specifically, a polyurethane foam which comprises a reaction product of a resin premix comprising the biopolyol in an amount of 5 to 30 wt % based on total weight of the resin premix, and a prepolymer. The antimicrobial bio polyurethane foam is enhanced in an antimicrobial property by maximizing the content of the biopolyol. | 2014-06-19 |
20140171532 | Method and apparatus for creating an improved fill for frameless furniture and the like - A fill material which includes first and second types of polymers which are mixed together to be used for filling frameless furniture or the like as well as the method and apparatus for making the fill material and supplying the fill material to a frameless furniture sheath. | 2014-06-19 |
20140171533 | METHOD FOR PRODUCING THERMOPLASTIC RESIN FOAMED BLOW-MOLDED ARTICLE AND THERMOPLASTIC RESIN FOAMED BLOW-MOLDED ARTICLE - Provided is a hollow foamed blow-molded article having a high heat resistance, employing a thermoplastic resin composition containing a mixed resin of a polyphenylene ether resin and a polystyrene resin, as a base resin. The foamed blow-molded article, may be produced by extruding a foamable molten resin composition obtained by kneading the thermoplastic resin composition and a blowing agent to form a foamed parison, and blow molding the foamed parison. A glass transition temperature of the thermoplastic resin composition is 110° C. or higher. A melt viscosity of the thermoplastic resin composition at a temperature of the glass transition temperature+80° C. and at a shear rate of 100/sec is 3000 to 9500 Pa·s. The physical blowing agent is a blowing agent containing a hydrocarbon compound having 3-5 carbon atoms. A blending amount of the physical blowing agent is 0.4 to 1 mol per kg of the thermoplastic resin composition. | 2014-06-19 |
20140171534 | POLYOLEFIN RESIN FOAM PARTICLES AND IN-MOLD FOAMING MOLDED BODY OF SAME - In order to obtain a flame-retardant polyolefin resin expanding molded product which has excellent in-mold moldability and excellent surface appearance and satisfies the FMVSS flammability even if carbon black is added, polyolefin resin particles containing, with respect to 100 parts by weight of polyolefin resin, (i) 0.03 part by weight to 5 parts by weight of phosphorous flame retardant having a phosphorous content of 7% by weight or more, a melting point of 120° C. or more, and a 5% by weight decomposition temperature within a range of 240° C. to 320° C. and (ii) 0.5 part by weight to 20 parts by weight of carbon black are expanded. | 2014-06-19 |
20140171535 | POLYOLS FROM BIOMASS AND POLYMERIC PRODUCTS PRODUCED THEREFROM - Polyol compositions containing methane linkages derived from amino acids. The polyols are obtained from the reaction of the carbonate with the cadres in the amino acids. Individual amino acids or mixtures of amino acids that are prepared from the hydrolysis of the proteins can be used. | 2014-06-19 |
20140171536 | Dental Restorative Materials Based on Polymerizable Azides and Alkynes - The invention relates to a dental restorative material on the basis of at least one compound of Formula I | 2014-06-19 |
20140171537 | Orange Curable Ink - An orange radiation curable ink including at least one curable monomer, at least one organic gellant, at least one photoinitiator, and at least one colorant, wherein the ink exhibits a reflectance on a substrate at a loading of from about 2 mg/inch | 2014-06-19 |
20140171538 | ADHESIVE COMPOSITIONS, ADHESIVE ARTICLES AND METHODS FOR MAKING THE SAME - Adhesive compositions comprising a high molecular weight acrylic copolymer and a low molecular weight copolymer are disclosed. Adhesive articles and methods of making adhesive compositions and articles are also described. | 2014-06-19 |
20140171539 | AMPHIPHILIC SILOXANE-CONTAINING (METH)ACRYLAMIDES AND USES THEREOF - The invention provides an amphiphilic siloxane-containing (meth)acrylamide which comprises one sole (meth)acrylamido group, one sole tris(trimethylsiloxy)silyl group, and one polyethylene glycol segment which is either dangling polymer chain or a hydrophilic linker between the (meth)acrylamido group and the tris(trimethylsiloxy)silyl group. The present invention is also related to a polymer, an actinically-crosslinkable silicone-containing prepolymer, a silicone hydrogel polymeric material, or a silicone hydrogel contact lens, which comprises monomeric units derived from an amphiphilic siloxane-containing (meth)acrylamido group, one tris(trimethylsiloxy)silyl group of the invention. In addition, the invention provides a method for making silicone hydrogel contact lenses using a water-based lens-forming formulation comprising an amphiphilic siloxane-containing (meth)acrylamido group, one tris(trimethylsiloxy)silyl group of the invention and/or an actinically-crosslinkable silicone-containing prepolymer of the invention. | 2014-06-19 |
20140171540 | LATEX COMPRISING WATER AND A STYRENIC BLOCK COPOLYMER AND A PROCESS FOR PREPARING ARTICLES THEREFROM - Articles with enhanced tensile strength and comfort are prepared from a latex comprising water and a styrenic block copolymer, wherein the styrenic block copolymer has 2 or more poly(vinyl aromatic) blocks and at least one block of polymerized conjugated diene wherein the styrenic block copolymer has a weight average molecular weight of 150,000 to 250,000, the poly(vinyl aromatic) blocks have a weight average molecular weight ranging from 9,000 to 15,000, and the content of poly(vinylaromatic) blocks in the styrenic block copolymer ranges from 8 to 15% wt, based on the total styrenic block copolymer, by a process which comprises coating a surface with the latex to obtain a film, wherein the latex comprises a vulcanising agent. The invention also provides a latex comprising such a styrenic block copolymer and a vulcanising agent, as well as a styrenic block copolymer that is particularly suitable for use in such a latex. | 2014-06-19 |
20140171541 | POLYMERIC ARTICLES COMPRISING OXYGEN PERMEABILITY ENHANCING PARTICLES - The present invention relates to a composition comprising a hydrogel polymer having less than 100% haze, and distributed therein an oxygen enhancing effective amount of oxygen permeable particles having an oxygen permeability of at least about 100 barrer, average particle size less than about 5000 nm. | 2014-06-19 |
20140171542 | AMPHIPHILIC SILOXANE-CONTAINING VINYLIC MONOMERS AND USES THEREOF - The invention provides an amphiphilic siloxane-containing vinylic monomer which comprises one sole ethylenically unsaturated group and a siloxane-containing group covalently linked to the ethylenically-unsaturated group through a hydrophilic linker. The present invention is also related to a polymer, an actinically-crosslinkable silicone-containing prepolymer, a silicone hydrogel polymeric material, or a silicone hydrogel contact lens, which comprises monomeric units derived from an amphiphilic siloxane-containing vinylic monomer of the invention. In addition, the invention provides a method for making silicone hydrogel contact lenses using a water-based lens-forming formulation comprising an amphiphilic siloxane-containing vinylic monomer of the invention and/or an actinically-crosslinkable silicone-containing prepolymer of the invention. | 2014-06-19 |
20140171543 | ACTINICALLY-CROSSLINKABLE AMPHIPHILIC PREPOLYMERS - The invention provide a class of actinically-crosslinkable amphiphilic prepolymers which comprise at least one polysiloxane segment, at least one polyoxazoline segment, and two terminal ene groups. The present invention is also related to a medical device comprising a silicone hydrogel material obtained from step-growth polymerization of a polymerizable material comprising a prepolymer of the invention and to a method for producing contact lenses from a prepolymer of the invention. | 2014-06-19 |
20140171544 | CONTACT LENS - A contact lens formed of a composition comprising the reaction product of: A) at least 10 weight percent, based on the total composition weight excluding solvent, of at least one silicone-containing monomer of the formula I: where n is from 1 to 3, m is from 9 to 15, each a independently is C | 2014-06-19 |
20140171545 | ANTIMICROBIAL FILLERS FOR PLASTICS - Enhanced fillers for plastics, their preparation and their use in plastic products imparting antimicrobial properties and improved tensile strength and other physical properties are presented. | 2014-06-19 |
20140171546 | Non-Yellowing easy-to-clean antimicrobial plastic - An additive that is incorporated into a thermoplastic acrylic pre-polymer formulation to render the polymer surface hydrophilic with easy cleanability and also making the surface antimicrobial. The additive is a hydrophilic reactive additive or (“HRA”), is incorporated with the other acrylic formulation components and polymerized into the acrylic polymer backbone. This reaction ensures that there will be no loss of hydrophilicity after repeated contact of the easy to clean acrylic sheet with water, as is typically happens with most sanitary ware products. | 2014-06-19 |
20140171547 | Bismuth Containing Complex and Condensation Reaction Curable Compositions and Methods for the Preparation and Use of the Compositions - A composition is capable of curing via condensation reaction. The composition uses a new condensation reaction catalyst. The new condensation reaction catalyst is used to replace conventional tin catalysts. The composition can react to form a gum, gel, rubber, or resin. | 2014-06-19 |
20140171548 | POLYOLEFIN-BASED THERMOPLASTIC ELASTOMER COMPOSITE AND COVER MATERIAL FOR AN AIR BAG USING SAME, AND AIR BAG MODULE USING THE COVER MATERIAL - The present invention relates to a polyolefin-based thermoplastic elastomer composition for a vehicle airbag cover, including a polypropylene-based resin, a denatured polypropylene resin, an ionomer resin, an olefin-based copolymer elastomer and a styrene-based copolymer elastomer, an airbag cover material using the composition, and an airbag module using the airbag cover material. | 2014-06-19 |
20140171549 | SIZING COMPOSITIONS AND METHODS OF THEIR USE - A sizing composition includes a texturing agent, a film-forming agent, and a cationic polymer having a polyalykyleneimine backbone. A glass fiber strand is formed from a plurality of individual glass fibers coated with the sizing composition. A composite material includes such glass fiber strands. | 2014-06-19 |
20140171550 | EPOXY RESIN WITH ENHANCED VISCOSITY STABILITY AND USE THEREOF - The present invention provides low polyphenols (such as bisphenol A) tougheners for epoxy adhesives. The tougheners, and adhesives comprising the tougheners exhibit enhanced viscosity stability, e.g., compared to tougheners prepared from higher amounts of bisphenol A (and epoxy adhesives comprising them). | 2014-06-19 |
20140171551 | Epoxy Resin Compositions Using Solvated Solids - An epoxy resin composition having a curing component and an epoxy component is disclosed. The curing component includes an amount of about 8% to about 70% by weight of the composition of a primary curing agent and about 0.001% to about 5% by weight of the composition of a secondary curing agent. The present disclosure includes the use of solid secondary curing agents, in particular solvated secondary curing agents, and methods to formulate such a solvated solid to result in a liquid curing component. The epoxy composition also includes about 30% to about 92% by weight of the composition of the epoxy component. A number of equivalents of reactive curative groups in the curing component is from about 0.50 to 0.98 times the number of epoxide equivalents present in the epoxy component. An epoxy product formed from the epoxy resin composition is also disclosed. | 2014-06-19 |
20140171552 | INDICATOR FOR CURE OF TWO-COMPONENT-EPOXY ADHESIVES - The subject matter of the present application is a cold-curing two-component-epoxy adhesive, comprising
| 2014-06-19 |
20140171553 | DRY MORTARS WITH LONG OPEN TIME AND INCREASED WATER FACTOR - The presently disclosed and claimed inventive concept(s) relates to a mixture composition for modifying a dry mortar formulation. The mixture composition comprises at least one redispersible polymer powder, a polyamide, a cellulose ether and a multivalent metal salt. The presently disclosed and claimed inventive concept(s) further relates a modified dry mortar formulation, a method of making the modified dry mortar formulation and a method of increasing the open time and water factor of the dry mortar formulation without deteriorating the mechanical strength of the cured dry mortar formulation. | 2014-06-19 |
20140171554 | HEAT AND PRESSURE GENERATED DESIGN - A wood fibre based panel with surfaces layer with lower parts which has less binders than the upper parts. Also, a method of manufacturing a building panel having a structured surface with a design that has colour variation in register with the structure obtained by a varying pressure distribution applied on the surface. | 2014-06-19 |
20140171555 | Water-Based Plaster - Provided is a water-based plaster in which the gel strength is maintained to an appropriate level in a step of producing the water-based plaster, and particularly in a spreading step and an aging step, and a final preparation can exhibit an optimal adhesiveness for adhering to the skin. In the water-based plaster, a water-based adhesive base containing a water-soluble polymer as a main ingredient contains a higher fatty acid which is a liquid at room temperature and a viscosity of 1,000 (mPa·s, 20° C.) or more as a crosslinking modifier. The higher fatty acid is isostearic acid, and the contained amount thereof is 1 to 10% by weight. | 2014-06-19 |
20140171556 | SULFUR-CROSSLINKABLE RUBBERIZING MIXTURE - A sulfur-crosslinkable rubberizing mixture for strengthening elements in motor vehicle pneumatic tires comprises 70 to 100 phr (parts by weight, based on 100 parts by weight of total rubbers in the mixture) of natural rubber, up to 30 phr of at least one polybutadiene, up to 15 phr of at least one carbon black, 20 to 100 phr of at least one high-dispersibility silica, at least one silane coupling agent and a bonding system. The invention further relates to motor vehicle pneumatic tires comprising the sulfur-crosslinked rubberizing mixture. For improved resistance to cracking and growth of cracks with good adhesion and good mechanical and dynamic properties, the high-dispersibility silica has a CTAB number to ASTM D 3765 of more than 130 m | 2014-06-19 |
20140171557 | TIRE WITH A TREAD COMPRISING AN EMULSION SBR HAVING A HIGH TRANS CONTENT - The present invention relates to a tyre, the tread of which comprises a rubber composition comprising at least:
| 2014-06-19 |
20140171558 | Ink Jet Recording Ink, Ink Jet Recording Ink Set, Recording Method, Recorded Matter and Ink Jet Recording Apparatus - An ink jet recording ink has excellent dispersion stability and ejection stability and is capable of providing images free from bleeding. Such an ink exhibits excellent color development and rubbing resistance. The ink jet recording ink comprises a pigment dispersed by a polymer; water; at least one compound selected from the group consisting of an acetylene glycol surfactant and an acetylene alcohol surfactant; and 1,2-hexanediol. The pigment dispersed by the polymer is produced by a phase conversion emulsification, an emulsion polymerization, an acid deposition or a forced emulsification. The ink has a surface tension between 25 mN/m and 45 mN/m. | 2014-06-19 |